These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38468867)

  • 21. Tumors of the peripheral nervous system: analysis of prognostic factors in a series with long-term follow-up and review of the literature.
    Montano N; D'Alessandris QG; D'Ercole M; Lauretti L; Pallini R; Di Bonaventura R; La Rocca G; Bianchi F; Fernandez E
    J Neurosurg; 2016 Aug; 125(2):363-71. PubMed ID: 26636382
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of (18)F-FDG PET and MRI in differentiating benign and malignant peripheral nerve sheath tumors.
    Broski SM; Johnson GB; Howe BM; Nathan MA; Wenger DE; Spinner RJ; Amrami KK
    Skeletal Radiol; 2016 Aug; 45(8):1097-105. PubMed ID: 27115884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
    Mautner VF; Asuagbor FA; Dombi E; Fünsterer C; Kluwe L; Wenzel R; Widemann BC; Friedman JM
    Neuro Oncol; 2008 Aug; 10(4):593-8. PubMed ID: 18559970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease.
    Schmidt H; Taubert H; Meye A; Würl P; Bache M; Bartel F; Holzhausen HJ; Hinze R
    Cancer Lett; 2000 Jul; 155(2):181-90. PubMed ID: 10822134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
    Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
    J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Atypical neurofibromas reveal distinct epigenetic features with proximity to benign peripheral nerve sheath tumor entities.
    Kresbach C; Dottermusch M; Eckhardt A; Ristow I; Paplomatas P; Altendorf L; Wefers AK; Bockmayr M; Belakhoua S; Tran I; Pohl L; Neyazi S; Bode H; Farschtschi S; Well L; Friedrich RE; Reuss D; Snuderl M; Hagel C; Mautner VF; Schüller U
    Neuro Oncol; 2023 Sep; 25(9):1644-1655. PubMed ID: 36866403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Image-Based Differentiation of Benign and Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1.
    Liu J; Huang JN; Wang MH; Ni ZY; Jiang WH; Chung M; Wei CJ; Wang ZC
    Front Oncol; 2022; 12():898971. PubMed ID: 35677169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diagnostic Quality of Magnetic Resonance Imaging Interpretation for Peripheral Nerve Sheath Tumors: Can Malignancy Be Determined?
    Karsy M; Guan J; Ravindra VM; Stilwill S; Mahan MA
    J Neurol Surg A Cent Eur Neurosurg; 2016 Nov; 77(6):495-504. PubMed ID: 27276118
    [No Abstract]   [Full Text] [Related]  

  • 29. Malignant peripheral nerve sheath tumors (MPNST) in neurofibromatosis type 1 (NF1): diagnostic findings on magnetic resonance images and mutation analysis of the NF1 gene.
    Friedrich RE; Kluwe L; Fünsterer C; Mautner VF
    Anticancer Res; 2005; 25(3A):1699-702. PubMed ID: 16033085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI.
    Matsumine A; Kusuzaki K; Nakamura T; Nakazora S; Niimi R; Matsubara T; Uchida K; Murata T; Kudawara I; Ueda T; Naka N; Araki N; Maeda M; Uchida A
    J Cancer Res Clin Oncol; 2009 Jul; 135(7):891-900. PubMed ID: 19101731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
    Nguyen R; Jett K; Harris GJ; Cai W; Friedman JM; Mautner VF
    J Neurooncol; 2014 Jan; 116(2):307-13. PubMed ID: 24166582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical evaluation of canine peripheral nerve sheath tumors and other soft tissue sarcomas.
    Chijiwa K; Uchida K; Tateyama S
    Vet Pathol; 2004 Jul; 41(4):307-18. PubMed ID: 15232130
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Computed Tomography-Based Differentiation of Benign and Malignant Craniofacial Lesions in Neurofibromatosis Type I Patients: A Machine Learning Approach.
    Wei CJ; Yan C; Tang Y; Wang W; Gu YH; Ren JY; Cui XW; Lian X; Liu J; Wang HJ; Gu B; Zan T; Li QF; Wang ZC
    Front Oncol; 2020; 10():1192. PubMed ID: 32850344
    [No Abstract]   [Full Text] [Related]  

  • 34. Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.
    Lu HC; Eulo V; Apicelli AJ; Pekmezci M; Tao Y; Luo J; Hirbe AC; Dahiya S
    Oncotarget; 2018 May; 9(33):23018-23028. PubMed ID: 29796169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feline cutaneous nerve sheath tumours: histological features and immunohistochemical evaluations.
    Mandara MT; Fabriani E; Pavone S; Pumarola M
    Res Vet Sci; 2013 Oct; 95(2):548-55. PubMed ID: 23659741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Whole body MRI with DWI in people with NF1 and Schwannomatosis: Are qualitative and quantitative imaging features of peripheral lesions comparable to localized MRI?
    Debs P; Fayad LM; Romo CG; Ahlawat S
    Eur J Radiol; 2023 May; 162():110802. PubMed ID: 37001256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Potential role of 18fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating benign neurofibroma from malignant peripheral nerve sheath tumor associated with neurofibromatosis 1.
    Karabatsou K; Kiehl TR; Wilson DM; Hendler A; Guha A
    Neurosurgery; 2009 Oct; 65(4 Suppl):A160-70. PubMed ID: 19927062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Silver Nanoparticles Selectively Treat Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors in a Neurofibromin-Dependent Manner.
    Alewine G; Knight J; Ghantae A; Mamrega C; Attiah B; Coover RA; Fahrenholtz CD
    J Pers Med; 2022 Jun; 12(7):. PubMed ID: 35887576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radiological findings of malignant peripheral nerve sheath tumor: reports of six cases and review of literature.
    Yu YH; Wu JT; Ye J; Chen MX
    World J Surg Oncol; 2016 May; 14():142. PubMed ID: 27159980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.